NDSIB
ALNY icon

North Dakota State Investment Board’s Alnylam Pharmaceuticals ALNY Stock Holding History

North Dakota State Investment Board’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
3,769
-275
-7% -$82.9K 0.05% 310
2026
Q1 		$1.34M Sell
4,044
-745
-16% -$254K 0.06% 256
2025
Q4 		$1.9M Buy
+4,789
New +$2.12M 0.07% 216

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

North Dakota State Investment Board's ALNY Position: Q2 2026 in Review

North Dakota State Investment Board reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.8% in Q2 2026, selling an estimated $82.9K and leaving 3,769 shares worth $1.13M. The position accounts for 0.05% of the portfolio, ranked #310.

North Dakota State Investment Board first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.9M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • North Dakota State Investment Board held 3,769 shares of Alnylam Pharmaceuticals worth $1.13M as of Q2 2026.
  • North Dakota State Investment Board sold 275 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $82.9K.
  • Alnylam Pharmaceuticals made up 0.05% of North Dakota State Investment Board's portfolio in Q2 2026, its #310 holding.
  • North Dakota State Investment Board first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • North Dakota State Investment Board's Alnylam Pharmaceuticals position peaked at $1.9M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on North Dakota State Investment Board's 13F filing for Q2 2026, filed 4 Aug 2026.